[Ip-health] MSF: Governments today to decide fate of nine million lives before AIDS summit

Joanna Keenan joanna.l.keenan at gmail.com
Mon Jun 6 15:45:27 PDT 2011

*Médecins Sans Frontières (MSF)/Doctors Without Borders PRESS RELEASE***

* *


*Latest Research Shows Expanded Treatment Could Turn AIDS Tide*

* *

*NEW YORK, June 6, 2011** –* At a time when HIV treatment has proven to
reduce HIV transmission by 96 percent, governments meeting for the UN Summit
on AIDS must agree today to put nine million people on treatment over the
next four years, despite strong opposition from several key funders, the
international medical humanitarian organization Médecins Sans Frontières
(MSF)/Doctors Without Borders said today.

“After weeks of contentious negotiations, will governments today sign up to
a proposed target to have 15 million people on HIV/AIDS treatment by 2015?”
asked Sharonann Lynch, HIV/AIDS policy advisor for MSF’s Campaign for Access
to Essential Medicines, speaking at a press conference at the UN in New
York. “The world needs an ambitious HIV/AIDS treatment target with a plan
attached to make it a reality – because it will be meaningless if countries
aren’t willing to come up with the cash and actions needed to break the back
of the epidemic.”

The summit comes on the heels of fresh scientific evidence that shows that
treatment is a form of prevention, as it reduces transmission of the virus
from one person to another by 96 percent.

“Over the last ten years, we’ve watched treatment save lives, and now we
know it can also protect entire communities, because treatment is
prevention.” said Dr. Tido von Schoen-Angerer, executive director of MSF’s
Campaign for Access to Essential Medicines, who worked in MSF’s first
HIV/AIDS treatment project in Thailand. “You’d have to be out of touch with
reality not to want to turn this landmark evidence about HIV treatment into
policies that will get ahead of the wave of new infections. Countries
meeting in New York have the power to change the course of the AIDS

An additional $6 billion will be needed each year by 2015 to help avert
twelve million new infections and more than seven million deaths by 2020,
according to new research by UNAIDS. This would also help bring the number
of annual infections down from 2.5 million in 2009, to one million by 2015.
However, funding in 2009 and 2010 declined, leaving the Global Fund to Fight
AIDS, TB and Malaria, the US-government’s PEPFAR and other programs short of
needed resources to make use of the benefits of ‘treatment as prevention.’

Governments also need to ensure the cost of medicines remains affordable.
Increased patenting of medicines is already impacting access to the newer
HIV/AIDS medicines needed to treat people as they navigate the life-long
disease. Newer drug combinations can cost nearly 50 times as much as the
first generation of drugs. Countries must immediately stop pushing trade
policies which block the production, export, transit, and importation of
more affordable generic medicines. Such policies are part of a number of new
bilateral free trade agreements, such as one currently under negotiation
between the European Union and India.

“Ten years ago, our patients came to clinics in wheelbarrows, often moments
away from death, because treatment was priced out of reach,” said Dr. von
Schoen-Angerer. “Thanks to affordable generic drugs, we’ve watched treatment
transform lives.  Rich countries need to stop the double-speak of claiming
to tackle HIV/AIDS when at the same time they are pushing policies that will
block the price-busting generic competition needed to get more people on
treatment for life.”

Governments must also stop opposing the implementation of strategies
directed toward groups most vulnerable in the epidemic – women, men who have
sex with men, people who inject drugs and sex workers.

“It’s way past high time for leaders to get their heads out of the sand when
it comes to the most marginalized groups affected by this plague,” said
Nonkosi Khumalo, chairperson of the Treatment Action Campaign in South
Africa.  “Treatment and prevention strategies targeting the most-at-risk
groups are irrelevant if you deny these people’s very existence.”

* *

*MSF currently provides antiretroviral treatment to 170,000 people living
with HIV/AIDS in 19 countries and sources more than 80 percent of the
antiretroviral medicines it uses in its projects from generic manufacturers
in India. *

* *

*To read MSF’s report – Getting Ahead of the Wave:  Lessons for the Next
Decade of the AIDS Response, visit
www.doctorswithoutborders.org/stopthevirus    *

* *

Joanna Keenan
Press Officer
Medecins Sans Frontieres
Campaign for Access to Essential Medicines
joanna.keenan [at] geneva.msf.org

More information about the Ip-health mailing list